Upstart Mind Cure Health (OTC:MCURF | CSE: MCUR) Set To Disrupt $300 Billion Industry 

“May revolutionize mental health care” - Fortune

One of the greatest shake-ups of the healthcare industry is underway. 

Top medical researchers have begun to focus on a unique, controversial, and potentially highly effective treatment for some of the world’s most complex and costly mental health conditions including addiction, depression, and PTSD.

Some of the world’s most prominent and successful Silicon Valley investors are backing it with hundreds of millions of dollars. 

One prominent analyst recently estimated the total size of this opportunity at $100 Billion.1

And today’s featured company, Mind Cure (OTC: MCURF | CSE: MCUR), is a small company that has positioned itself at the center of it all. 

And with a current market value of just C$33 million (US$25 million)2, this small upstart company has a lot of room to grow to catch up to its top competitors which have earned valuations of $1 billion and more. 

Mind Cure has already started the aggressive growth path with a few recent announcements and the markets are reacting. 

Mind Cure shares have steadily climbed as much as 200% since its Initial Public Offering (IPO) in September through to the start of December, but as you’ll see below, the company still has a lot of room to grow. 

This is an explosive situation, the window of opportunity is open, and now is the time to determine if it’s for you. 

First, let’s start at the beginning. 
Fortune Favors The Bold
Medicinal psychedelics are shaping up to be a potential game-changer in the $300 billion-per-year mental health industry. 

Bloomberg sums up the radical idea in piece titled Psychedelic Drugs Are Fueling a Mental Health Revolution from November 20203

Once deemed dangerous and illegal, psychedelic compounds have been rediscovered by the scientific, medical and psychiatric communities as research reveals their capacity to help patients with a range of maladies.

It’s more than a bit controversial, but historic research shows there’s real potential here.

And for investors looking for early-stage companies in rapidly growing sectors, Mind Cure (OTC: MCURF | CSE: MCUR), today’s featured company, has put itself at the heart of the psychedelics boom.

But here’s the key. 

Mind Cure is still valued at a small fraction of some of the billion-dollar-plus “unicorns” the medicinal psychedelics has already produced. 

READ: The Three Hottest Psychedelic Stocks That Every Investor Should Research

Big Money Backing Psychedelics

Medicinal psychedelics are a classic “special situation.”

They’re targeted at an industry – mental healthcare – that’s overdue for innovation. 

Early indications from clinical research say it could, as Fortune Magazine says, “revolutionize mental health care.”4

The research shows using medicinal psychedelics in a clinical setting can have a profoundly positive effect on mental health.

And they’ve earned the backing of the top Silicon Valley investors. 

For example, Peter Thiel, the first investor in Facebook (FB) and an early investor in Bitcoin and dozens of other tech giants, has backed two medicinal psychedelics companies. 

The first one he invested in, Compass Pathways (CMPS), is in FDA clinical trials.

And after raising more than $100 million in an Initial Public Offering (IPO) in October 2020 to accelerate its research, Compass Pathways has a market value of more than $2 BILLION today. 

Atai Life Sciences (privately held) is another company in this sector. 

The company just raised $125 million from some of the world’s most notable venture capitalists.

If it follows the same route as Compass Pathways, it will IPO in 2021 at a value well above $1 BILLION.6

Mind Medicine (OTC: MMEDF | CSE: MMED) is another leading medicinal psychedelics company. 

Mind Medicine is backed by Shark Tank star Kevin O’Leary.

And it has soared in value this year. Today it's worth $1.6 BILLION.7

But these are advanced companies with big funding. 

The best opportunity is looking to be in the small upstarts within medicinal psychedelics. 

That’s where Mind Cure comes in. 
Mind Cure (OTC: MCURF | CSE: MCUR) Has Room To Run In Psychedelics Race

Mind Cure is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of global mental health crisis.8

The company completed its IPO in September of 2020 and has been rapidly expanding with a focus on the five largest subsectors of the medicinal psychedelics market. 

Clinical Research

Mind Cure will be in position take the information it learns from customer feedback, academic research, and other sources and apply investigate to clinical research for the eventual development and targeting of new product candidates. 

The company recently took a big step towards developing this high-potential business secment too. 

Mind Cure recently announced it was going to open a psychedelics treatment clinic in 2021. 

The location will be in the psychedelics industry-friendly Canadian province of British Columbia. 

According to the announcement, the Kelowna, B.C. location “will offer psychedelic-assisted mental health therapy to patients as well as training to therapists.”

This is a big step forward for a company like Mind Cure and has the potential to establish a template for success in an industry with so much growth potential.  

Digital Therapeutics Technology

Clinical biotech researchers will tell you one of the biggest problems in researching and developing treatments of any kind for mental health is tracking and measurement of the efficacy of the treatment. 

Mind Cure has developed user-friendly software to much more actively that targeted at solving that problem. 

Formulation and Supply

Mind Cure is currently investigating and developing potential plans including the capital requirements, economics, and timelines for manufacturing, importing, and supplying traditional and novel psychoactive compounds (NPS).

These could include: LSD, NPS’s, MDMA, esketamine, Psilocybin DMT

Nootropic Formulations

Mind Cure has targeted nootropics as a place to stake out a share of the massive global nutritional health industry. 

A nootropic is a drug or supplement used to enhance cognitive function and fit right into Mind Cure’s aggressive growth strategy. 

Mind Cure’s products will be a functional mushroom powder sold under the Moombeam brand. Within the Moonbeam brand there will be targeted products offering specific benefits to consumers with Moonbeam Energy, Focus, and Protection types and we be a quick path to revenues.

Mind Cure has targeted broad range of outlets for distribution throughout the U.S and Canada.

The Company has received its Canadian Health Product Authorization Numbers (HPN) s, which authorizes the sale of natural products like functional mushrooms and  will be ramping up sales efforts through multiple channels. 

The first physical distribution point is through Body Energy Club franchises. The Body Energy Club has 17 locations in Canada and the United States. 

After that, Mind Cure has announced it will be targeting online sales and distribution directly to consumers and through Amazon, Google Shopping, eBay, Bonanza, and Walmart Marketplace. 

The total market for just the functional mushrooms is $23 billion per year and growing.

In the end, Mind Cure is a company structured in a way to ride the psychedelics boom in multiple ways.

For investors though, the potential opportunity in Mind Cure has an extra advantage over the multi-billion-dollar success stories like Compass Pathways and Mind Medicine we mentioned above. 
The Math Of An Exponential Growth Opportunity

For investors, Mind Cure’s advantage is its current valuation. 

Mind Cure shares were trading at the start of December 2020 at a price of C$0.60 (about US$0.45) each. 

The company has total shares outstanding of just under 55 million shares. 

So even though Mind Cure shares have TRIPLED from the IPO placement price of C$0.20 per share, the company has a market cap of just C$33 million ($25 million).

Relative to Compass Pathways ($2 billion) and Mind Medicine ($1.6 billion), Mind Cure has a lot more room to grow from this point. 

Based on these comparables, there is exponential growth potential from here. 

And the wind is still at the back of medicinal psychedelics startups too. 
The Rise Of Psychedelic-Derived Treatments

In the last few years top medical researchers have rediscovered the positive effects of Psychoactives and the healing power of psychedelics.

Consider a recent article from the Wall Street Journal – the investors paper of record. It reported that this new class of psychedelic-based drugs “can help alleviate depression, anxiety and addiction.”9

Fortune magazine – another seminal source for investors looking to maximize their returns – declared, “Psychedelic drugs may revolutionize mental health care.”10

And NBC News recently proclaimed, “Therapeutic ‘trips’ may someday bring relief from addiction, anxiety, depression — and even the fear of death.”11

And its not just the press either. 

Academia is also fully on board. Top researchers at Yale, Johns Hopkins, University of North Carolina,12 and many other top universities worldwide are paving the way forward for an entirely new class of drugs that can change the way we live, how well we live – and how long we live. 

The U.S. government has even started researching the remarkable power of psychedelics. 

In June of 2020 the Department of Defense’s Defense Advanced Research Projects Agency (DARPA) announced it would invest $26.9 million into researching medicinal applications for psychedelic drugs.

DARPA said its psychedelics research “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.”13

The rise of psychedelics is here.

There are years of growth ahead and, if psychedelics are as disruptive as some of the world’s top investors believe, there is exponential potential for early investors. 

That’s where Mind Cure (OTC: MCURF | CSE: MCUR) comes in because it’s just starting its growth trajectory.


Digital Therapeutics Industry Growth Forecast 

The pace of digital therapeutics adoption is accelerating beyond earlier forecasts. 

Digital Therapeutics are the new frontier in healthcare technology and have been a steadily-rising force within the healthcare sector. 

The Digital Therapeutics Alliance defines them as “evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions.”

Their increasingly proven potential as a better, more efficient, and more effective treatment option for the most costly and complex chronic physical and mental health conditions makes their broad adoption almost inevitable at this point.

The investor community is now waking up to the potential of Digital Therapeutics. 

Last year investments in healthcare startups hit $32.49 billion in a record total of 1,414 deals according to Silicon Valley Bank. 

McKinsey notes the potential of Digital Therapeutics being realized by investors when it reported, “Investors’ enthusiasm mirrors the growing demand for digital-therapeutic products and tools across the healthcare ecosystem.”

Mind Cure Enters Digital Therapeutics:

Mind Cure Health (OTC: MCURF | CSE: MCUR) recently announced it will be one of the newest entrants into Digital Therapeutics. 

Mind Cure is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of  global mental health crisis.

Mind Cure has stated it was starting the acquisition process for a company 
described as, “a proprietary cloud-based digital therapeutics platform for treating mental health.”
The company has been used by more than 10,000 patients over the last 20 years.
This move will give Mind Cure a direct stake in the rapidly rising Digital Therapeutics sector and complement its strategy to become a full-spectrum mental health and wellness company.


Mind Cure has released a series of announcements on new appointments, including some highly regarded individuals in the world of psychedelic drugs.
  • Kelsey Ramsden, two-time Top Female Entrepreneur in Canada, was named as Mind Cure’s new CEO
  • Dr. Ryan Hartwell, Award-Winning experimental scientist as Chief Science Officer
  • Dr. Dan Engle, a world-renowned physician in psychiatry and neurology deeply involved in psychedelic drug development, was appointed as an Advisor
  • Hamilton Morris, an award-winning journalist and psychedelics expert, was added as an Advisor
  • Dr. Jason Wallach, a prominent researcher and academic in psychedelic medicine, was also appointed as an Scientific Advisor
  • Dr. Wolfram Tetzlaff, a world-renowned researcher and scientist with decades of experience in neuroscience, known for his innovative and multidisciplinary approach as Scientific Advisor
  • Geoff Belair, a Fintech executive with deep experience in developing and operating new and innovative technologies in highly regulated industries 

A strong hand to guide operations. Leading minds – and voices – in the world of psychedelic medicine and psychedelic drug R&D.

Mind Cure is assembling the right cast for psychedelic drug success.




“Mind Cure believes the mental health space is ripe for innovation, and investment that could lead to major disruption in how mental health is treated.”
Mind Cure 2020

Consider Investing In Psychedelics Now

In the end, the entire opportunity in medicinal psychedelics is a simple one. 

The mental health care industry is long overdue for major innovation. 

Anti-depressants, many developed in the middle of the last century, have consistently proven to not be the most effective treatments or even possibly counterproductive in many cases.  

Psychedelics have the potential to be the disruptive force that shakes up the entire mental health sector. 

And now novel psychedelic treatments have attracted the financial backing of some of the biggest money investors in the world and can truly advance clinical research in psychedelics targeted at the most promising solutions. 

That final change – the surge of capital and investor awareness – has changed everything for all facets of the psychedelics industry. 

Companies like Mind Cure (OTC: MCURF | CSE: MCUR) may be positioned to ride the psychedelics boom all the way to the top too. 

All the best,

Dynamic Wealth Research Team

1 Analyst - $100 billion -
2 Mind Cure - 54 million s/o – Dec 1 avg price of C$0.60 (US$0.45 ) – C$33 million ($25 million)
3 Additional Sources – Bloomberg quote -
5 ATAI Life Sciences $125 million raise -
7 Mind Med – valuation – 359 million s/o @ US$4.50 (C$6.00) - $1.61 billion
8 Mind Cure Prospectus

Please see our full PRIVACY POLICY

The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.

Please see full disclaimers at applicable to all content provided by PSW , wherever published or re-published:

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.

PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.

PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.

This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.

© 2019 - 2021 Psychedelic Stock Watch, Privacy Policy, Disclaimer